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Abstract
Background: Anticancer activities of several substituted naphthalimides (1H-benz[de]isoquinoline-1,3-diones) are
well documented. Some of them have undergone Phase I-II clinical trials. Presently a series of ten N-(hydroxyalkyl)
naphthalimides (compounds 1a-j) were evaluated as antitumor agents.
Methods: Compounds 1a-j were initially screened in MOLT-4, HL-60 and U-937 human tumor cell lines and results
were compared with established clinical drugs. Cytotoxicities of compounds 1d and 1i were further evaluated in a
battery of human tumor cell lines and in normal human peripheral blood mononuclear cells. Cell cycle analysis of
compound 1i treated MOLT-4 cells was studied by flow cytometry. Its apoptosis inducing effect was carried out in
MOLT-4 and HL-60 cells by flow cytometry using annexin V-FITC/PI double staining method. The activities of
caspase-3 and caspase-6 in MOLT-4 cells following incubation with compound 1i were measured at different time
intervals. Morphology of the MOLT-4 cells after treatment with 1i was examined under light microscope and
transmission electron microscope.
3H-Thymidine and
3H-uridine incorporation in S-180 cells in vitro following
treatment with 8 μM concentration of compounds 1d and 1i were studied.
Results: 6-Nitro-2-(3-hydroxypropyl)-1H-benz[de]isoquinoline-1,3-dione (compound 1i), has exhibited maximum
activity as it induced significant cytotoxicity in 8 out of 13 cell lines employed. Interestingly it did not show any
cytotoxicity against human PBMC (IC50 value 273 μM). Cell cycle analysis of compound 1i treated MOLT-4 cells
demonstrated rise in sub-G1 fraction and concomitant accumulation of cells in S and G2/M phases, indicating up-
regulation of apoptosis along with mitotic arrest and/or delay in exit of daughter cells from mitotic cycle
respectively. Its apoptosis inducing effect was confirmed in flow cytometric study in MOLT-4 and the action was
mediated by activation of both caspase 3 and 6. Light and transmission electron microscopic studies corroborated
its apoptosis inducing efficacy at a concentration of 10 μM in MOLT-4 cells. Its apoptosis induction was also
observed in HL-60 cells to an extent much greater than well known apoptosis inducing agents as camptothecin
and cis-platin at 10 μM concentration each. It significantly inhibited DNA and RNA synthesis in S-180.
Conclusions: In essence, compound 1i showed potential as an antitumor agent.
Background
Development of an anticancer compound is always a fas-
cinating challenge in the field of cancer chemotherapy.
Research is ongoing globally to identify new leads. The
anticancer activities of several substituted naphthalimides
(1H-benz[de]isoquinoline-1,3-diones) are well documen-
ted [1,2]. For example, substituted naphthalimides
containing N-(2,2-dimethylaminoethyl) chain best repre-
sented by Mitonafide (5-nitro group in the aromatic ring)
and Amonafide (5-amino group in the aromatic ring)
have been shown to possess significant anticancer activ-
ities. Both Mitonafide [3,4] and Amonafide [5,6] have
undergone Phase I-II clinical trials with limited success.
We have recently reported appreciable antitumor activity
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and N-(3-chloropropyl) naphthalimides [7]. From the lit-
erature search, it was found that there was no report, to
our knowledge, that describes the anticancer potential of
known N-(2-hydroxyethyl) and N-(3-hydroxypropyl)
naphthalimides (compounds 1a-j). Hence we have under-
taken the present study of evaluating their potency. In
this report we have documented the findings that shows
that 6-nitro-2-(3-hydroxypropyl)-1H-benz[de]isoquino-
line-1,3-dione (compound 1i) is the most active member
in the series.
Materials and methods
Chemicals and drugs
A total number of ten substituted 2-(2-hydroxyethyl)-
and 2-(3-hydroxypropyl)-1H-benz[de]isoquinoline-1,3-
diones (compounds 1a-j) (Figure 1) were prepared
following established procedure. Out of these ten com-
pounds, test compound 1i [8] was most extensively
investigated. Mitonafide was received earlier as a gift
from Prof. M.F. Brana, University of San Pablo-CEU,
M a d r i d ,S p a i n .A n t i c a n c e rd r u g s ,p r o p i d i u mi o d i d ea n d
annexin V-FITC detection kit (A2214) were procured
from Sigma-Aldrich Corporation, St. Louis, MO, USA.
Culture of human tumor cell lines
The following human tumor cell lines namely Leukemia:
acute lymphoblastic MOLT-4, promyelocytic HL-60;
Lymphoma: histiocytic U-937; Breast: MCF-7; Neuro-
blastoma: IMR-32, SK-N-SH; Colon: 502713, COLO-
205, HCT-15, SW-620; Liver: Hep-2; Prostate: DU-145,
P C - 3a n dL u n g :A 5 4 9o b t a i n e de i t h e rf r o mN a t i o n a l
Centre of Cell Science (NCCS), Pune, India or National
Cancer Institute, Fredrick, MD, USA were used. Cell
l i n e sw e r eg r o w ni nt i s s u ec u l t u r ef l a s k si nR P M I - 1 6 4 0
medium with 2 mM glutamine (Invitrogen Corporation,
USA) containing 1% antibiotics (100 units penicillin/ml
and 100 μg streptomycin/ml, Cambrex Bioscience Inc.,
USA), pH 7.4, sterilized by filtration and supplemented
with 10% heat-inactivated fetal bovine serum (FBS, Invi-
trogen Corporation, USA) at 37°C in an atmosphere of
5% CO2/95% relative humidity in a CO2 incubator and
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Figure 1 Chemical structures of compounds 1a-j.
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Page 2 of 8routinely sub-cultured. Trypsin (0.02%) was used for dis-
lodging adherent type cells.
In vitro screening in human tumor cell lines
All the test compounds 1a-j were initially screened
against U-937 and HL-60 cell lines by MTT assay as per
standard procedure [9]. Compounds 1d and 1i were also
screened in MOLT-4 (Table 1). Drug stock solutions
(20 mg/ml) were prepared in cell culture DMSO. These
were serially diluted with complete growth medium sta-
ted above to obtain different drug concentrations [final
DMSO concentration was 0.5% highest to 0.001% low-
est]. Cells were seeded at 1 × 10
4 (U-937), 2 × 10
4
(HL-60) or 1 × 10
5 (MOLT-4) per well in 96-well cell
culture plates and incubated with respective drug solu-
tions of different concentrations for 96 hr and processed.
All vehicle controls contained same concentration of
DMSO. The plate was read in a microplate reader at 540
nm. Curvefit software was used to calculate the IC50
values. IC50 value < 10 μMi sc o n s i d e r e da sa c t i v ea sp e r
National Cancer Institute (NCI), USA, protocol.
Cytotoxicities of test compounds 1d and 1i were
further evaluated against 11 other human tumor cell
lines by SRB assay method [10] as stated in Table 2.
Growth inhibition value 50% or more at 1 × 10
-5Mi s
considered as active. Established anticancer drugs such
as doxorubicin, 5-FU, cis-platin, BCNU, hydroxyurea,
paclitaxel and mitomycin C were used in parallel for
comparison as indicated in the respective Table 1 and 2.
Effect on PBMC
PBMC was isolated from heparinized venous blood
obtained from healthy human volunteer by Ficoll-Paque
(Histopaque 1077, Sigma-Aldrich Corporation, St. Louis,
MO, USA.) density gradient centrifugation as per standard
procedure [11]. PBMC (1 × 10
5 cells/well) were cultured
in complete RPMI-1640 media as usual and incubated
with compounds 1d and 1i f o r4 8h rf o l l o w e db yM T T
assay. IC50 values were calculated using Curvefit software.
Analysis of cell cycle
The effect of compound 1i on different phases of cell
cycle of MOLT-4 was explored by flow cytometry [12].
In brief, 1 × 10
6 MOLT-4 cells were incubated with
compound 1i (10.0 and 16.7 μM )f o r2 4h ra n dc a m p -
tothecin (5 μM) for 3 hr. The cells were next washed
twice with ice-cold phosphate buffered saline (PBS), har-
vested, fixed with ice-cold PBS in 70% ethanol, and
stored at -20°C for 30 min. After fixation, the cells were
incubated with RNase A (Sigma-Aldrich Corporation,
St. Louis, MO, USA, 0.1 mg/ml) at 37°C for 30 min,
stained with propidium iodide (Sigma-Aldrich Corpora-
t i o n ,S t .L o u i s ,M O ,U S A ,5 0μg/ml) for 30 min on ice
in dark and analyzed for DNA content using BD-LSR
Flow cytometer (Becton Dickinson, USA). Data were
collected in list mode on 10,000 events and analyzed
using Mod Fit 2.0 software (Figure 2).
Assessment of apoptosis
Annexin V-FITC/PI double staining method was followed
[13] for the assay in MOLT-4 cells (1 × 10
6/well, 6-well
plate) after incubation of the cells with 10.0 and 16.7 μM
of compound 1i and 5 μM of camptothecin for 6 hr at
37°C (Figure 3). Similar assay was conducted in HL-60 by
using another apoptosis detection kit (BD Biosciences
Pharmingen, San Diego, USA). For this, HL-60 cells (5 ×
10
5/well) were treated for 24 hr with compounds 1i,c a m p -
tothecin and cis-platin (10 μM concentration each). Cells
were processed and stained with Annexin V-FITC/PI
according to the manufacturer’s instructions and analyzed
on a FACScan flow cytometer (Becton Dickinson, USA)
using Cell Quest software at two wavelengths 515 and 639
nm. Vehicle (DMSO) treated unstained and stained
[annexin V-FITC/PI] cells were used as controls (Figure 4).
Measurement of caspase-3/6 activities
The activities of caspase-3 and caspase-6 in MOLT-4 cells
(2 × 10
6/ml) following incubation with compound 1i (3.3 -
16.7 μM) and camptothecin (5 μM) for variable periods
were measured by using respective colorimetric assay kit
(R&D Systems, USA). Blank cell lysate control was also
included. Enzyme-catalyzed release of pNA was monitored
using a microplate reader at 405 nm (Figure 5A and 5B).
Cell morphological and ultra structural assessment
MOLT-4 cells were incubated with compound 1i
(10 μM) in DMSO for different time periods. Control
Table 1 In vitro screening in human tumor cell lines
IC50 value (μM)*
Compound Lymphoma Leukemia
U-937 HL-60 MOLT-4
1a 25.3 15.7 -
1b 37.5 19.3 -
1c 28.4 32.5 -
1d 1.4 0.7 4.2
1e 24.6 26.9 -
1f 32.7 17.6 -
1g 29.2 57.6 -
1h 36.9 26.0 -
1i 1.0 0.8 6.0
1j 18.6 39.9 -
Doxorubicin - - 11.0
5-FU 4.7 266 -
Cis-Platin 3.2 7.0 -
BCNU 12.3 30.5 -
Hydroxyurea 115 204 -
Mukherjee et al. Journal of Experimental & Clinical Cancer Research 2010, 29:175
http://www.jeccr.com/content/29/1/175
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cells were washed in PBS, centrifuged at 1500 rpm for
10 min. Pellets were divided into 1 mm
3 pieces and
fixed immediately in 2.5% glutaraldehyde in 0.1 M phos-
phate buffer (pH 7.2) for 2 hr at 4°C, post-fixed with 1%
OsO4 in the same buffer for 2 hr, dehydrated with acet-
one, cleared in propylene oxide and embedded in Epon-
812 [14]. Semithin (1 μm) sections were cut, stained
with toluidine blue and morphology of treated cells was
observed [14] at different times under light microscope
[Olympus, Japan]. Photomicrographs were taken with
Olympus Digital Camera (C4000) (Figure 6). Ultrathin
sections of silver color (60-90 nm) were cut on a LKB
ultramicrotome IV, mounted on copper grids and
stained with uranyl acetate and lead citrate. The sections
were viewed and photographed in a JEOL-100CXII elec-
tron microscope at 60 kV (Figure 7).
3H-Thymidine and
3H-Uridine incorporation in S-180 cells
in vitro
S-180 tumor cells maintained in vivo in Swiss albino mice
were used for incorporation of
3H-thymidine and
3H-
uridine (specific activity 1.0 mCi/ml each, obtained from
Board of Radiation and Isotope Technology, Mumbai,
India) following treatment with 8 μM concentration of
compounds 1d and 1i as described earlier [15]. Mitonafide
at the same concentration was used for comparison.
Abbreviations used
MTT: [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetra-
zolium bromide]; SRB: sulphorhodamine B; DMSO:
dimethylsulfoxide; S-180: Sarcoma-180; PBMC: peripheral
blood mononuclear cells; IC50: 50% inhibitory
Table 2 In vitro screening in human tumor cell lines
Compound Conc. (M) Breast Neuroblastoma Liver Colon Lung Prostate
MCF-7 IMR-32 SK-N-SH Hep-2 502713 Colo-205 HCT-15 SW-620 A549 DU-145 PC-3
Growth inhibition (%)*
1d 1×1 0
-6 03 2 0 - - 8 4 - 0--
1×1 0
-5 23 69 41 - - 64 29 - 23 - -
1i 1×1 0
-6 15 71 45 5 43 26 12 34 - 34 0
1×1 0
-5 24 39 89 26 84 23 24 56 - 53 51
5-FU 1 × 10
-5 30 - 66 - 45 - - 26 - - -
Paclitaxel 1 × 10
-6 -7 2 - - - - 7 66 2 6 2--
Mitomycin C 1 × 10
-6 - - 50 - - 43 - 71 - 58 46
1×1 0
-5 60 - 85 49 - - 70 - - - -
Doxorubicin 1 × 10
-6 37 - 51 64 - - - - - - -
1×1 0
-5 - - - - - - 47 - - - 70
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Figure 2 Flow cytometric assessment of cell cycle of MOLT-4
cells (1 × 10
6/ml) treated in vitro with compound 1i (10.0 and
16.7 μM) for 24 h or camptothecin (5.0 μM) for 3 hr as
reference. Treatment with compound 1i resulted in marked rise in
sub-G1, S and G2/M fractions suggesting apoptosis and mitotic
delay, respectively.
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Figure 3 Induction of apoptosis by compound 1i (10.0 and
16.7 μM) and camptothecin (5.0 μM) in MOLT-4 cells (1 × 10
6/
well). Live, apoptotic and necrotic cells were analyzed by flow
cytometry after staining with annexin V-FITC and propidium iodide.
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Page 4 of 8concentration; 5-FU: 5-Fluorouracil; BCNU: bis(2-chlor-
othyl)nitrosourea.
Statistical analysis
Values were recorded as the mean ± S.E.M. (standard
error mean) of three experiments. Experimental results
were analyzed by Student’st - t e s t .P<0 . 0 5w a sc o n s i d -
ered as the level of significance for values obtained for
treated groups compared with control group.
Results
Cytotoxicity screening
In vitro screening of compounds 1a-j against U-937 and
HL-60 revealed that compounds 1a-c, 1e-1h and 1j did
not show appreciable activity as their IC50 values were
above 10 μM. Compounds 1d and 1i having IC50 values
in the range of 0.7 and 6.0 μM in U-937, HL-60 and
MOLT-4 were found to be cytotoxic (Table 1). The IC50
values of compounds 1d and 1i were much less than
that of doxorubicin, 5-FU, cis-platin, BCNU and hydro-
xyurea used as standards (Table 1) suggesting greater
antitumor properties in compounds 1d and 1i.I nv i e w
of this, compounds 1d and 1i were selected for further
screening in a battery of human tumor cell lines. The
results summarized in Table 2 revealed that compound
1d has elicited significant growth inhibition in two
(IMR-32 and COLO-205) out of six cell lines used while
compound 1i elicited significant growth inhibition in
five (SK-N-SH; 502713, SW-620, DU-145 and PC-3) out
of ten cell lines tested. It appears that compound 1i is
the most active member.
In vitro toxicity screening in PBMC
Compounds 1d and 1i showed high IC50 values of 698
and 273 μM respectively against human PBMC in vitro
suggesting that these compounds were devoid of signifi-
cant cytotoxicity against normal cells.
Effect on cell cycle
MOLT-4 cells exposed to 10.0 and 16.7 μM of compound
1i for 24 hr exhibited increase in sub-G1 fraction which
may comprise of both apoptotic cells and cell debris
implying up-regulation of cell death machinery. The effect
was much more for the higher concentration of the com-
pound. For instance, the sub-G1 fractions of control and
camptothecin-treated cells were 0.68% and 11.92% respec-
tively whereas the same were 4.69% and 21.02% for com-
pound 1i at the low and high concentrations (Figure 2).
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Figure 4 Analysis of apoptosis induced by compounds in
HL-60 cells (5 × 10
5/well) by flow cytometry using annexin
V-FITC and PI. Quadrant analysis of fluorescence intensity of gated
cells in FL-1 (annexin V-FITC) and FL-2 (PI) channels was from 10,000
events. A: Stained control; B: Camptothecin (10 μM); C: Cisplatin:
(10 μM); D: 1i (10 μM).
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Figure 5 a Caspase 3 and b caspase 6 activities in MOLT-4 cells
(2 × 10
6/ml) treated with 5.0 μM compound 1i and 5.0 μMo f
camptothecin (reference) for 2-24 h in vitro.
a
b
Figure 6 Photomicrographs of a control and b compound 1i
treated MOLT-4 cells exposed to 10 μM of compound for 36 h
in vitro. Compared with control cells with large nuclei (N) and
prominent nucleoli, treated cells displayed marginalized chromatin
material (arrow) and cytoplasmic vaculation (V), the hallmark of
apoptosis. (Mag. 1000×).
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sis of MOLT-4 cells inflicted by compound 1i. The cell
cycle analysis also showed accumulation of treated cells in
S and G2/M phases. Increase in S phase fraction could be
due to stimulation of DNA synthesis or delay in move-
ment of cells from S to G2/M phase. Concomitant rise in
G2/M fraction indicates delay in exit of daughter cells
from the mitotic cycle. Therefore the findings suggest
delayed turnover of cells leading to reduction of tumor
cell number.
Analysis of apoptosis in MOLT-4 and HL-60 cells by
Annexin V-FITC/PI double staining method
MOLT-4 and HL-60 control and treated cells were
stained with annexin V-FITC/PI and gated into LR
(Lower Right) and UR (Upper Right) quadrants. Cells
in LR and UR were considered as early apoptotic
(annexin
+/PI
-) and late apoptotic (annexin
+/PI
+)
respectively. Extent of apoptosis was expressed as the
sum total of the percentages in LR and UR quadrants.
Cells in LL (Lower Left) and UL (Upper Left) quad-
rants were considered live and necrotic respectively.
Apoptosis induced by compound 1i was compared
with that of camptothecin (Figure 3) and camptothecin
and cis-platin used as standards (Figure 4). Apoptosis
recorded in untreated control MOLT-4 and HL-60
cells were 3.61% and 2.54% respectively.
In MOLT-4, total apoptosis exhibited by camptothecin
at 5 mM concentration was 8.89%. In contrast com-
pound 1i at 10.0 and 16.7 mM concentrations was effec-
tive in inducing 27.54% and 30.86% apoptosis
respectively. The necrotic cell populations for com-
pound 1i at these doses were 5.15% and 4.80% respec-
tively (Figure 3).
In HL-60, compound 1i induced 98.62% apoptosis at a
dose of 10 μM (LR 3.49%, UR 95.13%). This is in con-
trast to 15.82% and 7.51% apoptosis respectively induced
by camptothecin and cisplatin at the same dose. Thus
compound 1i was more effective than standards in indu-
cing apoptosis in HL-60 (Figure 4).
Activation of caspases
Treatment of MOLT-4 cells with compound 1i was
associated with marked increase in caspase-3 as well as
caspase-6 activities that confirm the apoptotic mode of
cell death. Up-regulation of caspase-3 by compound 1i
was maximum at 5.0 μM concentration at 12 hr post-
treatment (Figure 5a) while caspase-6 activity was high-
est also at 5.0 μM concentration at 24 hr post-treatment
(Figure 5b). Similar activations were produced by camp-
tothecin at 5.0 μM concentration (Figure 5a-b).
Cell morphological and ultra structural assessment
The morphology of MOLT-4 cells treated with com-
pound 1i at 5 and 10 μM was monitored by light micro-
scopy at different time points. The number of apoptotic
cells increased with higher concentration of the com-
pound and longer incubation period. Figure 6b repre-
sents the characteristic morphology of apoptotic cells
following 36 hr of incubation at 10 μM concentration.
Marginalization of chromatin material accompanied by
cell shrinkage, nuclear condensation/fragmentation and
formation of cytoplasmic vacuoles, considered as hall-
mark of apoptosis, were clearly visible. Control cells
showed large sized nuclei having nucleoli (Figure 6a).
In transmission electron microscopy, MOLT-4 control
cells (Figure 7a-b) exhibited a high nucleocytoplasmic
ratio and the nucleus had a finely dispersed chromatin
with nuclear pores. The nucleoli were clearly visible in
most of the cells. The mitochondria with cristae (MC)
in various size and shape (oval and elongated), rough
endoplasmic reticulum and ribosomes were seen.
MOLT-4 cells treated with 10 μMo fc o m p o u n d1i for
36 h revealed damaged mitochondrial cristae and highly
reduced rough endoplasmic reticulum suggesting apop-
tosis (Figure 7c-f). No inflammatory changes in nuclei
and cytoplasm coupled with absence of breakage in
Figure 7 TEM of control and compound 1i treated (10 μMf o r
36 h) MOLT-4 cells showing internal ultra structure. The control
cells show nucleus (N) with finely dispersed chromatin material and
a nucleolus (Nu). The mitochondria with cristae (MC) and ribosomes
(R) are seen (Figure A-B). The treatment causes chromatin
marginalization (CM), condensation of the nucleus (CN), and
vacuolization (V) in the cytoplasm (Figure C-F).
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events. Vacuolization was also seen in treated cells. Lit-
erature survey also revealed similar observations [16,17].
Inhibition of DNA/RNA synthesis in S-180 tumor cells
in vitro
Since compound 1d and 1i have structural similarity
with mitonafide, studies were conducted to ascertain
whether drug-induced tumor growth inhibition was also
due to the inhibitory effect of these compounds on
nucleic acid synthesis. Accordingly
3H-thymidine and
3H-uridine incorporation by S-180 cells collected from
untreated tumor bearing mice was measured after treat-
ing the tumor cells in vitro. The untreated S-180 cells
demonstrated an almost linear pattern of
3H-thymidine
and
3H-uridine incorporation over a period of 60 min.
Exposure of tumor cells to test compounds at the con-
centration of 8 μM resulted in gradual and marked inhi-
bition of
3H-thymidine and
3H-uridine incorporation
comparable to that of mitonafide at the same concentra-
tion (8 μM). After 1 hr of incubation with compound 1d
and 1i
3H-thymidine incorporation was declined by 96%
and 95% respectively against 95% reduction by mitona-
fide exposure. Thus the compounds showed remarkable
inhibitory effect on DNA synthesis. Inhibition of RNA
synthesis, in contrast was less spectacular as inhibition
of
3H-uridine was 92%, 94% and 89% for mitonafide,
compound 1d and 1i respectively (Figure 8).
Discussion
The nature and position of a substituent in a molecule
are known to play important roles in deciding its antitu-
mor property. The present study has shown that out of
the five different substituents (R = H, 6-Br, 6-Cl, 6-NO2,
5-NO2) present in the aromatic ring portion of substi-
tuted N-(hydroxyalkyl)naphthalimide moiety, the 6-NO2
substituent is crucial in exercising the antitumor activity.
This is in agreement with our earlier finding in other
(chloroalkyl) naphthalimide compounds wherein we
found 6-nitro-2-(3-chloropropyl) naphthalimide as the
most active antitumor agent in that series [7].
Compound 1i that showed most pronounced antitu-
mor activity interfered with S and G2/M phases of cell
cycle of MOLT-4 cells. As a preparatory step towards
cell division, a cell duplicates its DNA in S phase of cell
cycle. Thus, interference of S phase by compound 1i as
observed in flow cytometric measurements, suggests
that it affects DNA duplication process of tumor cell
before mitosis. This possibility was confirmed in S-180
cells in which compound 1i inhibited
3H-thymidine
incorporation into DNA, implying suppression of DNA
synthesis. Moreover, it inhibited
3H-uridine uptake, indi-
cating concomitant inhibition of RNA synthesis. Taken
together, the results suggest that inhibition of DNA and
RNA might have played a role in mediating the antitu-
mor effect of compound 1i.
D e l a yi ne x i tf r o mG 2/M, the final phase of cell cycle,
was another flow cytometric observation in compound
1i treated MOLT-4 cells. A situation like this develops
when there is defect in DNA damage repair, spindle
attachment with centromeres and polymerization of
spindle microtubules [18]. In view of these reports, it
appears that the compound has adverse effect on the
mitotic apparatus causing up-regulation of the spindle
checkpoint control leading to delayed mitotic exit of
daughter cells. It is known that vinca alkaloids [19] and
paclitaxel [20] mediate their antitumor effects by inter-
fering with spindle microtubules. Compound 1i may act
in a similar fashion like them.
Induction of apoptosis or programmed cell death is a
common mechanistic pathway of several antitumor
agents [21]. Compound 1i h a se x e r t e di t sa n t i t u m o r
action by this pathway as well. This is evident from
sharp rise in sub-G1 fraction, light and electron micro-
scopic studies showing morphological imprints of apop-
tosis and marked increase in caspase 3 and 6 in treated
cells. Apoptosis is controlled by a diverse range of cell
signals which may originate intracellularly via the mito-
chondria or extracellularly via death receptors on cell
membranes. These two pathways of signals converge
and form a common irreversible execution phase
mediated by caspase 3 and 6. Whether the pro-apoptotic
signal elicited by compound 1i followed the intrinsic
(mitochondrial) or extrinsic (death receptor) pathway is
not clearly understood. However, extensive damage of
mitochondrial cristae in treated cells, as observed in
ultrastructural study, favours mitochondrial pathway.
Like the present finding, induction of apoptosis by many
naphthalimides including amonafide and amonafide ana-
logs has been reported [22,23].
In essence, the present study demonstrated significant
antitumor activity by compound 1i against murine
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Figure 8 Effects of compound 1d, 1i and Mitonafide at 8 μM
concentration each on the synthesis of DNA and RNA in S-180
tumor cells. Results are expressed as percentage of
3H-thymidine
and
3H-uridine incorporation in untreated control cells.
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Page 7 of 8S-180 tumor cells and a panel of human tumor cell lines
in vitro and the effect was mediated by inhibition of cell
proliferation and up-regulation of programmed cell
death. Since the compound did not elicit any cytotoxi-
city against normal human PBMC, it holds promise for
further development as a potential antitumor agent.
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